Review of NICE Technology Appraisal Guidance No 158; Oseltamivir, amantadine and zanamivir for the prophylaxis of influenza (including a review of TA67)

The review date for this guidance is September 2011. 

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal. 

The new clinical evidence that has been published since TA158 was issued is consistent with the conclusions by the Appraisal Committee on the clinical effectiveness of oseltamivir and zanamivir. There have been no relevant changes to the price of oseltamivir, zanamivir or amantadine, and no information is available about any changes to the marketing authorisations or any relevant new or ongoing trials of the effectiveness of these drugs. Based on this information, it is proposed that the guidance is placed on the static list. 

Topics on the static list may be transferred back to the active list for further consideration if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.  Please see appendix A for a full list of the organisations we have contacted. 

October 2011